WinstonWınston
Back
Euroapi S.A. logo

Euroapi S.A.

EAPIF
22
Medical - Devices · Healthcare
Price
$1.17
+0.00 (+0.00%)
Market Cap
$111.8M
Exchange
Other OTC
Winston Score
22
Winston is worried
Weak fundamentals across most pillars.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Weak
Growth
Weak
Cash Flow
Weak
Stability
Good
Valuation
Data not available

Winston Score History

The full picture

Euroapi is a French company that makes the active ingredients found inside medicines — the actual chemical compounds that make drugs work. These ingredients, called active pharmaceutical ingredients (APIs), are sold to pharmaceutical companies around the world who use them to manufacture finished pills, injections, and other treatments. Euroapi was spun off from Sanofi in 2022 and is one of Europe's largest API manufacturers.

The company earns revenue by selling APIs and providing contract development and manufacturing services to drugmakers. It operates primarily in Europe, with production sites in France, Germany, Hungary, Italy, and Spain. Its main competitive advantage is its broad chemistry expertise and established customer relationships, though its thin gross margins and negative operating margin show the business is under financial pressure. The key challenge ahead is improving profitability by cutting costs and winning new long-term manufacturing contracts, while facing competition from lower-cost Asian producers.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-14.1% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-400.0% YoY

YoY Growth Rate

Earnings declining

R&D Spend

€27M/ year

Rising (+6% vs prior year)

3.2% of revenue

Below sector average (18%)

R&D investment increasing — building for the future

Insider Activity

47.0%ownership

Insiders own a meaningful stake in the company

Cash Runway

~1 months

€52M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Euroapi S.A. has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

+0.7% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 94.0M (2021) → 94.7M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
15.7%
Thin — 15.7% gross margin
Profit after running costs
Operating Margin
-2.4%
Losing money on operations — -2.4%
Return on the money invested
ROCE
2.5%
Weak — 2.5% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-10.3%
Shrinking sales (-10.3% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
-4.6%
Burning cash (-4.6%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.14
Conservative — low debt load (0.14)
Covers its interest
Interest Cover
1.08x
Dangerous — barely covers interest (1.1x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial